Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

IGM Biosciences (NASDAQ:IGMS) lost nearly two-thirds of its value on Friday after the company abandoned two antibody-based ...

The company is reducing its workforce by 73% and evaluating strategic alternatives to preserve shareholder value.

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold ...

Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3)– – Company reducing its workforce by 73% –– Cash and ...

Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as ...

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including ...

IGM Biosciences has decided to halt development of imvotamab and IGM-2644, two IgM-based bispecific antibody T cell engagers for autoimmune diseases, and cut its staff by 73%. The biotechnology ...

Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat ...